Sign in Register

Drug class

Bradykinin B2 Receptor Antagonists (Acute)

Bradykinin B2 receptor antagonists (acute) represent a specialized pharmacologic class of targeted agents designed for the on-demand management of acute, episodic swelling. Read more about Bradykinin B2 Receptor Antagonists (Acute)

8 drugs in this class 8 manufacturers

Related classes & indications

Iron Chelating AgentsOther therapeutic classes · 45 prescription drugs Phosphodiesterase-4 (PDE4) inhibitorsOther therapeutic classes · 20 prescription drugs Hereditary AngioedemaTop indication · 21 prescription drugs

Showing 1–8 of 8 drugs

Sort

FIRAZYR (icatibant acetate)

BRADYKININ B2 RECEPTOR ANTAGONISTS (ACUTE) · HEREDITARY ANGIOEDEMA

SHIRE US INC.

ICATIBANT (icatibant acetate)

BRADYKININ B2 RECEPTOR ANTAGONISTS (ACUTE) · HEREDITARY ANGIOEDEMA

TEVA USA

SAJAZIR (icatibant acetate)

BRADYKININ B2 RECEPTOR ANTAGONISTS (ACUTE) · HEREDITARY ANGIOEDEMA

CYCLE PHARMACEU

ICATIBANT (icatibant acetate)

BRADYKININ B2 RECEPTOR ANTAGONISTS (ACUTE) · HEREDITARY ANGIOEDEMA

CIPLA USA, INC.

ICATIBANT (icatibant acetate)

BRADYKININ B2 RECEPTOR ANTAGONISTS (ACUTE) · HEREDITARY ANGIOEDEMA

LEUCADIA/HIKMA

ICATIBANT (icatibant acetate)

BRADYKININ B2 RECEPTOR ANTAGONISTS (ACUTE) · HEREDITARY ANGIOEDEMA

FRESENIUS KABI

ICATIBANT (icatibant acetate)

BRADYKININ B2 RECEPTOR ANTAGONISTS (ACUTE) · HEREDITARY ANGIOEDEMA

ALEMBIC PHARMAC

FIRAZYR (icatibant acetate)

BRADYKININ B2 RECEPTOR ANTAGONISTS (ACUTE) · HEREDITARY ANGIOEDEMA

Takeda Pharmaceuticals America

Filter & compare in the drug finder → Opens the drug finder with Bradykinin B2 Receptor Antagonists (Acute) preselected. Add indication or manufacturer filters there.

About Bradykinin B2 Receptor Antagonists (Acute).

Bradykinin B2 receptor antagonists (acute) represent a specialized pharmacologic class of targeted agents designed for the on-demand management of acute, episodic swelling.

These drugs function by competitively and selectively binding to vascular bradykinin B2 receptors, thereby blocking the downstream effects of excessive bradykinin signaling, such as vasodilation, microvascular hyperpermeability, and tissue edema.

Clinically, this class is primarily established and approved for treating acute attacks of hereditary angioedema in adults and pediatric patients, rapidly arresting and relieving cutaneous, abdominal, and potentially life-threatening laryngeal edema episodes.

contemporarypediatrics.com
Bradykinin B2 receptor antagonists (acute) represent a specialized pharmacologic class of targeted agents designed for the on-demand management of acute, episodic swelling These drugs function by competitively and selectively binding to vascular bradykinin B2 receptors, thereby blocking the downstream effects of excessive bradykinin signaling, such as vasodilation, microvascular hyperpermeability, and tissue edema
rxlist.com
Bradykinin B2 receptor antagonists (acute) represent a specialized pharmacologic class of targeted agents designed for the on-demand management of acute, episodic swelling
fda.gov
These drugs function by competitively and selectively binding to vascular bradykinin B2 receptors, thereby blocking the downstream effects of excessive bradykinin signaling, such as vasodilation, microvascular hyperpermeability, and tissue edema
fiercepharma.com
These drugs function by competitively and selectively binding to vascular bradykinin B2 receptors, thereby blocking the downstream effects of excessive bradykinin signaling, such as vasodilation, microvascular hyperpermeability, and tissue edema
firazyr.com
Clinically, this class is primarily established and approved for treating acute attacks of hereditary angioedema in adults and pediatric patients
data.gov
Clinically, this class is primarily established and approved for treating acute attacks of hereditary angioedema in adults and pediatric patients
fda.gov
Clinically, this class is primarily established and approved for treating acute attacks of hereditary angioedema in adults and pediatric patients, rapidly arresting and relieving cutaneous, abdominal, and potentially life-threatening laryngeal edema episodes
nih.gov
Clinically, this class is primarily established and approved for treating acute attacks of hereditary angioedema in adults and pediatric patients, rapidly arresting and relieving cutaneous, abdominal, and potentially life-threatening laryngeal edema episodes
pcori.org
Clinically, this class is primarily established and approved for treating acute attacks of hereditary angioedema in adults and pediatric patients, rapidly arresting and relieving cutaneous, abdominal, and potentially life-threatening laryngeal edema episodes